Drugs such as Pazopanib which acts on inhibiting intracellular tyrosine kinase of VEGFR and PDGFR would be an interesting way to treat patients with meningiomatosis, as PDGFR and FGFR pathways are dependent on SMARCB1 loss, and this agent is currently being looked at in a cancer known as atypical teratoid rhabdoid tumor (ATRT) [65]. Here, SMARCB1 is linked to cancer.